UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Plus Therapeutics, Inc. (the “Company”) informs its investors that it does not have exposure to Silicon Valley Bank. The Company does not hold cash deposits or securities with Silicon Valley Bank, and does not otherwise have a business relationship with Silicon Valley Bank.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Plus Therapeutics, Inc. |
|
|
|
|
Date: |
March 13, 2023 |
By: |
/s/ Marc H. Hedrick, M.D. |
|
|
Name: Title: |
Marc H. Hedrick, M.D. |
Document And Entity Information |
Mar. 10, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 10, 2023 |
Entity Registrant Name | PLUS THERAPEUTICS, INC. |
Entity Central Index Key | 0001095981 |
Entity Emerging Growth Company | false |
Securities Act File Number | 001-34375 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 33-0827593 |
Entity Address, Address Line One | 4200 Marathon Blvd. |
Entity Address, Address Line Two | Suite 200 |
Entity Address, City or Town | Austin |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 78756 |
City Area Code | (737) |
Local Phone Number | 255-7194 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | PSTV |
Security Exchange Name | NONE |
]S%/B6!&3#=\71M
M/>QP*D,!??LBW7;2UC2"#=-PK(JV-YJV TX<0H!$- Y9-^$5DQ1M)\PNA<5VV@NJ-%AD[>+:H"4ENCH"#S7DX]D+K*
MA?1&[OHX]2"6UC,HUF(SIU[H[2J'7=;4OJD'<6_M@^(M-W(^%KQS*+SS4>#S
M=1):]!W3Y@. :ZLGM.QYP^8#X!?45&@3T'DU=:904&F19=>Y,W5"E]9?9-&+
M[9DZ$\A7962I=^R8.E$/JM7(TN]W9>I,2%_!D",3']N]O'U_.$=>?5A%%"RPDX:QK."W;0)@%/"1L
MUC6^C,S>J#\8&)]NKJY_,DUT>S]X0D]XB7J!(@M\2V1 N4P$1N]&C^_1US^'
M#^B!L.\37V)TRX,DPDPA$\V5BCN6M5PN6^&4,,EIHJ!#V0IX9"'3W#;?%]C7
M[]&MKS#JN+;KF;9G.O;8:7<\K^.Y+==K.[_8=L>V]ZKQ>"W(;*[0N^ ]TK6@
M;\8PI6MT3YC/ N)3-,HZ_14-6-!"/4K14->2:(@E%@L